Intranasal Oxytocin in Antiosocial Personality Disorder and Psychopathy

• Status: Completed
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

A pharmacoimaging study of oxytcoin in antisocial personality disorder and psychopathy

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: King's College London
• Collaborator: Father Flanagan's Boys' Home
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Male

• Aged 18-60

• IQ greater than 70 as defined by the Wechsler Abbreviated Scale of Intelligence (WASI-II).

Violent offenders:

Offenders with convictions for violent crimes (murder, rape, attempted murder, grievous and actual bodily harm) who met DSM-5 criteria for antisocial personality disorder (Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5 PD) Psychopathy or non-psychopathy subgroup based on Psychopathy Checklist- Revised (PCL-R; (Hare, 2003))- score of 25 as the threshold for psychopathy in this English population.

Healthy non-offenders:

Non-offenders with no personality disorder

Exclusion criteria:

• history of major mental disorders (bipolar 1, bipolar 2, major depression or psychotic disorders)

• self-reported neurological disorders

• head injury resulting in loss of consciousness for 1 hour or longer

• severe visual or hearing impairments

• contraindications to MRI